Abstract 572P
Background
Lung cancer was the leading cause of mortality in 2022, with 38.4% of patients having non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line treatment for EGFR-mutated NSCLC. A limited number of patients achieved five-year survival. This retrospective study aimed to provide real-world evidence and explore the factors affecting the five-year survival of patients with EGFR-mutated NSCLC.
Methods
This study included patients with EGFR-mutated NSCLC treated in Chang Gung Memorial Hospitals between 2011 and 2016, ensuring at least five years of follow-up or mortality. Odds ratios (ORs) were calculated using univariate and multivariate analyses. A scoring system based on a logistic regression model was designed to evaluate factor weightings on patients’ five-year survival. Their overall survival probability was estimated using the Kaplan-Meier model. The model’s accuracy was assessed using the area under the receiver operating characteristic curve (AUC).
Results
Of 1,873 enrolled patients, 185 were lost to follow-up within five years, leaving 1,787 for analysis. Of patients achieving five-year survival, more were female, age 65 years, had performance scores of 0∼1, no metastases, and adequate objective responses and disease control. A scoring system was developed by assigning points to each prognostic factor associated with increased risk of not achieving five-year survival: age > 65 years (1 point); performance score of 2∼4 (2 points); stage IV disease (1 point); liver (2 points), bone (1 point), or pleura (1 point) metastasis; and poor disease control (2 points). In the Kaplan-Meier model, the estimated five-year survival rate was 39.4%, 13.0%, 7.2%, and 2.2% for the low-risk (0∼1 point), intermediate-risk (2 points), high-risk (3 points), and very-high-risk (4∼10 points) groups, respectively. The prediction model’s AUC was 0.787 (95% CI: 0.752∼0.821), indicating fair accuracy.
Conclusions
We proposed a scoring system based on real-world data for predicting the five-year survival of patients with EGFR-mutated NSCLC treated with EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chang Gung Memorial Hospital (Linkou Branch).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract